Welcome to our dedicated page for Kala Pharmaceuticals news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on Kala Pharmaceuticals stock.
KALA BIO, Inc. (NASDAQ: KALA) generates news that spans clinical trial developments, strategic reviews, financing transactions and capital structure changes in the ophthalmology-focused biopharmaceutical space. As a clinical-stage company centered on rare and severe eye diseases, its updates often revolve around the progress and outcomes of its investigational programs and the funding required to support them.
A major theme in recent KALA news has been the development of KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy studied for persistent corneal epithelial defect (PCED). The company has reported on milestones such as completion of enrollment in the CHASE Phase 2b trial and, later, topline results showing that the study did not meet its primary or key secondary endpoints. These disclosures were accompanied by announcements about ceasing development of KPI-012 and the MSC-S platform, workforce reductions and an evaluation of strategic options.
Another significant stream of news involves financing and restructuring. KALA has issued press releases on a registered direct offering of common stock, a securities purchase agreement for non-voting convertible preferred stock, and a convertible loan agreement, as well as updates on a loan settlement with Oxford Finance LLC that resolved substantial debt obligations. Leadership and governance changes, including appointments in executive roles and board positions, have also been reported.
Investors and followers of KALA BIO’s news can expect coverage related to clinical data readouts, regulatory designations, Nasdaq listing compliance matters, debt settlements, equity offerings and strategic transaction discussions. Monitoring this news flow provides context on the company’s evolving pipeline priorities, financial position and potential corporate actions. For an ongoing view of these developments, readers can review the chronological news feed associated with the KALA ticker.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced the grant of non-statutory stock options to four new employees, totaling 42,000 shares. These options, with an exercise price of $8.01 per share, were provided as inducement awards outside the 2017 Equity Incentive Plan, in line with NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, the options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. Kala focuses on innovative therapies for eye diseases, including its product INVELTYS and the investigational EYSUVIS, for which a New Drug Application is under FDA review with a target action date of October 30, 2020.